rdf:type |
|
lifeskim:mentions |
umls-concept:C0015915,
umls-concept:C0019927,
umls-concept:C0023610,
umls-concept:C0031809,
umls-concept:C0205065,
umls-concept:C0205232,
umls-concept:C0332161,
umls-concept:C0458083,
umls-concept:C1274040,
umls-concept:C1511572,
umls-concept:C1955120,
umls-concept:C2347957
|
pubmed:issue |
5
|
pubmed:dateCreated |
2003-11-10
|
pubmed:abstractText |
To identify the cut-off values of the baseline (cycle day 3) levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E(2)) for improving the outcome prediction of GnRH antagonist in vitro fertilization (IVF) cycles and to determine whether the predictive accuracy of these values is affected by the patient's clinical prognosis.
|
pubmed:commentsCorrections |
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
0015-0282
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1156-61
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading |
pubmed-meshheading:14607567-Adult,
pubmed-meshheading:14607567-Area Under Curve,
pubmed-meshheading:14607567-Estradiol,
pubmed-meshheading:14607567-Female,
pubmed-meshheading:14607567-Fertilization in Vitro,
pubmed-meshheading:14607567-Follicle Stimulating Hormone,
pubmed-meshheading:14607567-Gonadotropin-Releasing Hormone,
pubmed-meshheading:14607567-Humans,
pubmed-meshheading:14607567-Infertility, Female,
pubmed-meshheading:14607567-Luteinizing Hormone,
pubmed-meshheading:14607567-Menstrual Cycle,
pubmed-meshheading:14607567-Ovary,
pubmed-meshheading:14607567-Predictive Value of Tests,
pubmed-meshheading:14607567-Pregnancy,
pubmed-meshheading:14607567-Prognosis,
pubmed-meshheading:14607567-ROC Curve,
pubmed-meshheading:14607567-Retrospective Studies,
pubmed-meshheading:14607567-Treatment Outcome
|
pubmed:year |
2003
|
pubmed:articleTitle |
Fine tuning cycle day 3 hormonal assessment of ovarian reserve improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles.
|
pubmed:affiliation |
Department of Gynecology and Obstetrics, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA.
|
pubmed:publicationType |
Journal Article
|